Alluvi, known as BI 4744, presents a promising development in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates https://bookmarkingalpha.com/story22121736/alluvi-a-detailed-dive-into-retatrutide-s-prospects